Cover image of the article: Phage Therapy in COVID-19 Treatment

Image Credit:Int J Infect

Phage Therapy in COVID-19 Treatment

Authors

Yara Elahi1, Ramin Mazaheri Nezhad FardRamin Mazaheri Nezhad Fard ORCID2,*
1Department of Genetics, Faculty of Life Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran
2Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: raminmazaheri@gmail.com

International Journal of Infection:Vol. 9, issue 1; e116630
Published online:Nov 17, 2021
Article type:Letter
Received:Jul 20, 2021
Accepted:Nov 04, 2021
How to Cite:Elahi Y, Mazaheri Nezhad Fard R. Phage Therapy in COVID-19 Treatment. Int J Infect. 2022;9(1):e116630. doi: https://doi.org/10.5812/iji.116630

Dear Editor,
Since the global outbreak of coronavirus in 2019, several studies have been carried out on this newly-emerged viral infection. However, no definitive cures have been reported for this deadly virus. Currently, the possible method to prevent further coronavirus spread and avoid its high mortality rate is vaccination. Despite efforts by governments and vaccine manufacturers to facilitate vaccination progress, it seems that further years are necessary to complete whole-nation vaccination schemes. Mass vaccination has become a challenge for governments because the number of highly effective vaccines is very limited. Moreover, vaccine sources are monopolized by developed countries. However, researchers have realized that even vaccination is not a perfect solution to prevent re-infections with the virus. Because coronaviruses are not likely to be completely eradicated due to their rapid evolution, alternative therapies seem necessary. Therefore, the use of bacteriophages (phages) as one of these alternative therapies might open up new horizons in front of medical specialists. Studies have verified that phages include antiviral and antifungal properties and their antibacterial properties (1). Phage therapy has recently been reported as an effective technique in suppressing the activation of nuclear factor kappa-light-chain-enhancer of activated B cells to build up immunity against viral pathogens. The upregulation of defensin 2 due to the phage therapy induces antiviral immunity (2). Based on recent studies, phages can be used for the production of artificial antibodies (Ab) in the primary stages of this viral infection (3). The antiviral potential of phages can be used to treat viral infections that affect the respiratory tract. Relatively, suggestions have been made for the production of phage-based vaccines (2). In conclusion, phage therapy can be an appropriate solution for treating viral infections, including coronavirus disease 2019. However, further studies are needed to better understand phage-therapy mechanisms and verify their sufficient effectiveness in the treatment of urgent viral infections.

Footnotes

  • Authors' Contribution: Study concept and design: Y.E.; Analysis and interpretation of the data: R.MNF. and Y.E.; Drafting of the manuscript: Y.E.; Critical revision of the manuscript for important intellectual content: R.MNF.; Statistical analysis: Y.E.

  • Conflict of Interests: The authors declare no conflict of interest.

  • Funding/Support: This study was not supported by any grant.

References

Copyright

Copyright © 2021, International Journal of Infection. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Similar Articles

10
Oct
2020
Potential Drugs for Treating COVID-19 Infection

Potential Drugs for Treating COVID-19 Infection

Mehrdad Mohammadi,
Tim Sandle,
Sajad Rajabi,
Ahmad Khorshidi,
Ahmad Piroozmand

Mohammadi M, Sandle T, Rajabi S, Khorshidi A, Piroozmand A. Potential Drugs for Treating COVID-19 Infection. Int J Infect. 2020;7(4):e106243. doi: https://doi.org/10.5812/iji.106243

9
Apr
2020
Review of therapeutic agents for the treatment of COVID-19

Review of therapeutic agents for the treatment of COVID-19

Shadi Ziaie,
Mehran Kouchek,
Mir Mohammad Miri,
Sara Salarian,
Seyed pouzhia Shojaei,
Mehrdad Haghighi
,et al.

Ziaie S, Kouchek M, Miri MM, Salarian S, Shojaei SP, et al. Review of therapeutic agents for the treatment of COVID-19. J Cell Mol Anesth. 2020;5(1):e151378. doi: https://doi.org/10.22037/jcma.v5i1.29760

31
Jan
2020

Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces

Farzaneh Dastan,
Payam Tabarsi,
Majid Marjani,
Afshin Moniri,
Seyed Mohammad Reza Hashemian,
Maria Tavakoli-Ardakani
,et al.

Dastan F, Tabarsi P, Marjani M, Moniri A, Hashemian SMR, et al. Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. Iran J Pharm Res. 2020;19(1):e124449. doi: https://doi.org/10.22037/ijpr.2020.113369.14259

24
Jan
2021
Antiviral Vector Effects of Ivermectin on COVID-19: An Update

Antiviral Vector Effects of Ivermectin on COVID-19: An Update

Fatemeh Heidary,
Reza Gharebaghi,
Mohammed Lateef,
Mustafa Zain Alabden Mohammed,
Sarah Fawzi Hasan Alshmailawi,
Kahtan Alkhafaji
,et al.

Heidary F, Gharebaghi R, Lateef M, Zain Alabden Mohammed M, Fawzi Hasan Alshmailawi S, et al. Antiviral Vector Effects of Ivermectin on COVID-19: An Update. J Cell Mol Anesth. 2021;6(1):e150288. doi: https://doi.org/10.22037/jcma.v6i1.33827

25
Apr
2020
The Current Clinically Relevant Findings on COVID-19 Pandemic

The Current Clinically Relevant Findings on COVID-19 Pandemic

Joseph V. Pergolizzi Jr.,
Peter Magnusson,
Jo Ann LeQuang,
Frank Breve,
Antonella Paladini,
Martina Rekatsina
,et al.

Pergolizzi Jr. JV, Magnusson P, LeQuang JA, Breve F, Paladini A, et al. The Current Clinically Relevant Findings on COVID-19 Pandemic. Anesth Pain Med. 2020;10(2):e103819. doi: https://doi.org/10.5812/aapm.103819

More by these authors

Yara ElahiPubMedScholar
Ramin Mazaheri Nezhad FardPubMedScholar
Share
Cited by
Metrics